Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

Leonard Schleifer; Co-Chairman of the Board, President, Chief Executive Officer, Founder; Regeneron Pharmaceuticals Inc George Yancopoulos; Co-Chairman of the Board, President, Chief Scientific ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Net Income: $1.4 billion in Q4 2024, with diluted net income per ... 2025 Effective Tax Rate Guidance: 11% to 13%. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported a strong fourth quarter ...

Leonard Schleifer; Co-Chairman of the Board, President, Chief Executive Officer, Founder; Regeneron Pharmaceuticals Inc George Yancopoulos; Co-Chairman of the Board, President, Chief Scientific ...

Net Income: $1.4 billion in Q4 2024, with diluted net income per share of $12.07 ... 2025 Effective Tax Rate Guidance: 11% to 13%. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported a strong fourth ...

BofA raised the firm’s price target on Regeneron (REGN) to $575 from $565 and keeps an Underperform rating on the shares. Q4 results were “good,” but FY25 guidance was “not very useful ...